A phase 2, randomized, double-blind study comparing Tremelimumab to placebo in Second- or third-line treatment of subjects with unresectable pleural or peritoneal malignant mesothelioma
Clinical Trial Grant
Awarded By
MedImmune, Inc.
Start Date
October 1, 2013
End Date
April 21, 2017
Awarded By
MedImmune, Inc.
Start Date
October 1, 2013
End Date
April 21, 2017